Hemant Makan

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes7 trials
• Obesity3 trials
• Chronic kidney disease1 trial
• Type 1 diabetes1 trial

Phase

• Phase 38 trials

Status

• Completed7 trials
• Active, not recruiting1 trial

Lead sponsor

• Novo Nordisk A/S8 trials

Running trials

• Recruiting

  A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  NCT07564414· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

Closed trials

• Completed

  A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

  NCT06340854· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

  NCT06323161· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

  NCT05646706· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

  NCT05649137· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

  NCT05352815· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source